Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PGEN
PRECIGEN, INC.
NASDAQ
$6.95
▼ DOWN 3.34% (-0.24)

KEY STATISTICS

Market Cap$2.48 B
52w High$7.72
52w Low$2.99
Dividend Yield—
Frequency—
P/E-6.34
Volume2.70M
Shares Out.356.51M

COMPANY

LEADERSHIP

Helen Sabzevari
CHIEF EXECUTIVE
Helen Sabzevari

COMPENSATION 2026

Salary$1,000,000
Stock Awards$2,215,000
Incentive Plan Pay$1,049,997
All Other Comp.$20,132
Total$5,354,329

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 8, 2013
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
160

PRICE TARGET

Target High$18.00
Target Low$18.00
Target Median$18.00
Target Consensus$18.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$69.21M
NOV
12
THU

PRICE

$6.95 ▼ DOWN 3.34% (−$0.24)
$6.97$7.05$7.139:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM6.95

About Precigen, Inc.

https://www.precigen.com ↗

Precigen, Inc. develops innovative gene and cellular therapies, platforms, and engineered biologics for medical and regenerative applications through advanced genetic technologies and strategic collaborations.

INDUSTRY

Biotechnology

A PRODUCT PRECIGEN, INC. IS KNOWN FOR

PAPZIMEOS™ (zopapogene imadenovec)
PAPZIMEOS™ (zopapogene imadenovec)

PAPZIMEOS, FDA-approved gene therapy for adults with Recurrent Respiratory Papillomatosis, is Precigen’s flagship product, offering a groundbreaking, single-treatment alternative to repeated surgeries for this rare disease.

COMPETITORS

COMPETITOR
BMRN COMPARE
CRSP COMPARE
INO COMPARE
QURE COMPARE
SRPT COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q1-2026Q2-2026
Product— — $21.83M $53.26M ▲
Service— — $1.42M $1.72M ▲
Biopharmaceuticals Segment$1.34M — — —
Exemplar Segment$1.06M — — —
Operating Segments— $856K — —

Revenue by Geography

MapREGIONQ3-2022Q4-2022Q1-2026Q2-2026
NonUS$63K $16K ▼$279K ▲$165K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
118
LISTED HERE
22
RANKED BY POSITION SIZE
XBI
0.46% · 7.6M
VTS.AX
0.00% · 5.7M
IWM
0.04% · 4.9M
FYC
0.81% · 1.7M
GR
GRNJ
1.59% · 1.2M
SCHA
0.03% · 854.5K
BBP
1.98% · 329.0K
LABU
0.31% · 274.6K
XRSG.L
0.04% · 182.7K
ONEQ
0.01% · 127.4K
ISMD
0.26% · 120.9K
RSSL
0.04% · 92.2K
GSSC
0.05% · 69.4K
BBSC
0.05% · 52.0K
QQQS
0.80% · 25.8K
ADDS
1.88% · 18.5K
BIB
0.09% · 12.7K
RFLR
0.09% · 12.5K
VETS
0.07% · 4.9K
AVTM
0.00% · 3.0K
USFMDN.MX
0.00% · 958
RESM
0.04% · 311

INSTITUTIONAL OWNERSHIP

SHARES OWNED
58.91%
HOLDERS
278
TOP 12 OF 278 · RANKED BY POSITION SIZE
Third Security, LLC
83.5M sh · $176.95M
Patient Capital Management, LLC
26.5M sh · $87.06M
Blackrock, Inc.
17.1M sh · $97.74M
Point72 Asset Management, L.P.
13.7M sh · $57.37M
Tang Capital Management LLC
12.4M sh · $40.8M
State Street Corp
12.0M sh · $68.41M
Vanguard Group Inc
10.5M sh · $43.8M
Blackrock Inc.
10.2M sh · $16.19M
Diametric Capital, LP
9.3M sh · $52.84M
Boxer Capital Management, LLC
5.2M sh · $29.36M
Geode Capital Management, LLC
5.0M sh · $28.61M
Fmr LLC
4.7M sh · $19.45M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
KINDLER JEFFREY B
Sale · 185.0K shares
2026-08-26
★
OFFICER: CHIEF COMMERCIAL OFFICER
Tennant Phil
Sale · 79.2K shares
2026-08-25
★
OFFICER: PRESIDENT AND CEO
Sabzevari Helen
Sale · 10.2K shares
2026-08-23
★
OFFICER: CHIEF FINANCIAL OFFICER
Thomasian Harry Jr.
Sale · 7.3K shares
2026-08-23

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
MARKET OUTPERFORM 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
DNTH$105.84COMPARE
ELVN$57.86COMPARE
RLAY$18.77COMPARE
AMLX$34.74COMPARE
NKTR$72.52COMPARE
ORIC$13.24COMPARE
IMTX$9.45COMPARE
WVE$5.04COMPARE